在2026年AACR会议上,Antengene提出了三种新的癌症治疗方法. Antengene presents three new cancer therapies at the 2026 AACR meeting.

在2026年美国癌症研究协会年度会议上,Antengene介绍了三种新的癌症治疗方法. At the 2026 American Association for Cancer Research Annual Meeting, Antengene presented three new cancer therapies. 抗体ATG-125是一种针对瘤细胞和免疫检查点的双特异性抗体,在临床前模型中显示出强烈结果. ATG-125 is a bispecific antibody targeting tumor cells and immune checkpoints, showing strong results in preclinical models. 基-106和ATG-112是针对硬体瘤 (如脏癌和卵巢癌) 的T细胞诱导剂,显示出更安全,更有效的治疗潜力. ATG-106 and ATG-112 are T cell engagers designed for solid tumors like kidney and ovarian cancers, demonstrating the potential for safer and more effective treatments.